RT Journal Article
SR Electronic
T1 3PO as a Selective Inhibitor of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma Cells
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2613
OP 2625
DO 10.21873/anticanres.14232
VO 40
IS 5
A1 KOTOWSKI, KRZYSZTOF
A1 SUPPLITT, STANISŁAW
A1 WICZEW, DANIEL
A1 PRZYSTUPSKI, DAWID
A1 BARTOSIK, WERONIKA
A1 SACZKO, JOLANTA
A1 ROSSOWSKA, JOANNA
A1 DRĄG-ZALESIŃSKA, MAŁGORZATA
A1 MICHEL, OLGA
A1 KULBACKA, JULITA
YR 2020
UL http://ar.iiarjournals.org/content/40/5/2613.abstract
AB Background/Aim: The occurrence of BRAFV600E mutation causes an up-regulation of the B-raf kinase activity leading to the stabilization of hypoxia-inducible factor 1-alpha (HIF-1α) - the promoter of the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) enzyme. The aim of the study was to examine the effect of the (2E)-3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), as an inhibitor of PFKFB3, on human melanoma cells (A375) with endogenous BRAFV600E mutation. Materials and Methods: A375 cells were exposed to different concentrations of 3PO and the following tests were performed: docking, cytotoxicity assay, immunocytochemistry staining glucose uptake, clonogenic assay, holotomography imaging, and flow cytometry. Results: Our studies revealed that 3PO presents a dose-dependent and time-independent cytotoxic effect and promotes apoptosis of A375 cells. Furthermore, the obtained data indicate that 3PO induces cell cycle arrest in G1/0 and glucose uptake reduction. Conclusion: Taking all together, our research demonstrated a here should be proapoptotic and antiproliferative effect of 3PO on A375 human melanoma cells.